Boehringer Ingelheim International Gmbh

Neurocrine Biosciences, Inc.

Bernd Nosse

Gerald Juergen Roth

Martin Thomas Fleck

Niklas Heine

Frank Himmelsbach

Elke Langkopf

Thorsten Lehmann-Lintz

Neil Ashweek

Nicole Harriott

Matthias Eckhardt

Armin Heckel

Heike Neubauer

Annekatrin Charlotte Heimann

Andreas Blum

Klaus Rudolf

Leo Thomas

Dirk Stenkamp

Joerg Kley

Stefan Scheuerer

Steffen Breitfelder

Heather Tye

Marcus Schindler

Bernd Wellenzohn

Alexander Heifetz

Juergen Prestle

Stephan-Georg Mueller

Christopher John Brown

Natacha Prevost

Neil J Ashweek

Christoper John Brown

Compounds of formula I wherein R, L, n, HetAr, and HetArare as defined herein, and salts thereof, pharmaceutical compositions containing these compounds, and methods for treating diseases or conditions which are mediated by activating the G-protein-coupled receptor GPR119, such as diabetes, dislipidemia, or obesity, by administering to a patient in need thereof these compounds or a pharmaceutically acceptable salt thereof.

N-cyclopropyl-N-piperidinyl-amides, pharmaceutical compositions containing them and uses thereof

The present invention relates to compounds of general formula (I), wherein R, L, L, (Het)Ar, m and n are as defined in the application, which have valuable pharmacological properties, and in particular bind to the GPR1 19 receptor and modulate its activity. 

N-cyclopropyl-N-piperidinyl-amides, pharmaceutical compositions containing them, and uses thereof

The present invention relates to compounds defined by formula I wherein the groups X, Y, W and Rto Rare defined as in claim, possessing valuable pharmacological activity. Particularly the compounds are agonists of the 5-HT2C receptor, and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this receptor, such as metabolic and CNS-related disorders.

6,7,8,9-tetrahydro-5H-1,4,7,10a-tetraaza-cyclohept[f]indene derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them

Pyrrolidine derivatives which are inhibitors of acetyl-CoA carboxylase(s) and their use in the treatment of obesity and type-2 diabetes. An exemplary compound is 2-(4-(1-[5-Chloro-6-(2-hydroxy-2-methyl-propoxy)-pyrimidin-4-yl]-(R)-pyrrolidin-3-yloxy)-phenyl)-N-cyclopropyl-propionamide.

Pyrrolidine derivatives, pharmaceutical compositions and uses thereof

Pyrrolidine derivatives of the formula and their use as medicaments for the treatment of obesity and type 2 diabetes.

The present invention relates to compounds of general formula I, wherein the groups R, R, and A are as defined in the application, which have valuable pharmacological properties, and in particular bind to the GPR119 receptor and modulate its activity.

Compounds, pharmaceutical compositions and uses thereof

The invention relates to new piperidine derivatives of the formula I to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.

The invention relates to new pyrrolidine derivatives of the formula wherein Rto R, Ar, L T and n are as defined in the description and claims, to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.

Pyrimidine-substituted pyrrolidine derivatives, pharmaceutical compositions and uses thereof

The present invention relates to compounds of general formula I, wherein R, L, HetAr, Ar, and n are as defined in the application, which have valuable pharmacological properties, and in particular bind to the GPR119 receptor and modulate its activity.

N-cyclopropyl-N-piperidinyl-amide derivatives, pharmaceutical compositions and uses thereof

The invention relates to new compounds of the formula I to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.

The invention relates to new pyrrolidine derivatives of the formula to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.

The present invention relates to compounds of general formula I, wherein the groups R, L, L, Ar, m and n are as defined in the application, which have valuable pharmacological properties, and in particular bind to the GPR119 receptor and modulate its activity.

The present invention relates to compounds of general formula I, wherein the groups R, L, L, X, X, X, A, n and m are as defined in the application. The compounds of formula I have valuable pharmacological properties, and in particular bind to the GPR119 receptor and modulate its activity.

Piperidine derivatives of which the following is exemplary and their use in the treatment of obesity, diabetes or dyslipidemia.

Growing community of inventors

Biberach an der Riss, Germany

Bernd Nosse